Heparin is a compound of defined chemical structure and pharmaceutical significance whose toxicological characterisation supports health-based exposure limit derivation for pharmaceutical manufacturing occupational safety and cross-contamination control. The relationship between molecular structure and biological potency—assessed through structure-activity relationship analysis and experimental pharmacological and toxicological data—determines the OEB classification and the engineering containment requirements governing manufacturing operations involving Heparin.
PDE derivation for Heparin applies the composite uncertainty factor methodology: F1 accounts for interspecies pharmacokinetic and pharmacodynamic differences (default 12 for rat-to-human, refinable with toxicokinetic AUC bridging data), F2 covers intraspecies variability in the human population including sensitive subgroups (default 10), F3 adjusts for study duration relative to chronic exposure (1 for chronic studies, up to
